On November 28th, Eli Lilly announced positive results in the Phase 2 clinical trial of muvallaplalin. Muvallaplalin is a once daily oral medication under development for reducing lipoprotein (a) [Lp (a)]. Lp (a) is a genetically related risk factor associated with cardiovascular disease. Research has shown that muvallaplalin can significantly reduce adult Lp (a) levels, achieving the primary endpoint [i.e. percentage change in Lp (a) from baseline to week 12].